Symbols / DARE $1.74 -8.42% Daré Bioscience, Inc.
DARE Chart
About
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 25.33M |
| Enterprise Value | 3.28M | Income | -13.40M | Sales | 1.03M |
| Book/sh | 0.20 | Cash/sh | 1.70 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 1.91 | PEG | — |
| P/S | 24.59 | P/B | 8.88 | P/C | — |
| EV/EBITDA | -0.28 | EV/Sales | 3.18 | Quick Ratio | 1.07 |
| Current Ratio | 1.14 | Debt/Eq | 93.44 | LT Debt/Eq | — |
| EPS (ttm) | -1.20 | EPS next Y | 0.91 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-12 | ROA | -31.04% |
| ROE | — | ROIC | — | Gross Margin | 71.29% |
| Oper. Margin | -143.72% | Profit Margin | 0.00% | Shs Outstand | 14.56M |
| Shs Float | 13.31M | Short Float | 1.49% | Short Ratio | 2.99 |
| Short Interest | — | 52W High | 9.19 | 52W Low | 1.27 |
| Beta | 0.90 | Avg Volume | 86.72K | Volume | 94.40K |
| Target Price | $9.67 | Recom | Strong_buy | Prev Close | $1.90 |
| Price | $1.74 | Change | -8.42% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.67
Mean price target
2. Current target
$1.74
Latest analyst target
3. DCF / Fair value
$-5.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.74
Low
$8.00
High
$12.00
Mean
$9.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-04 | up | Maxim Group | Hold → Buy | $8 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-17 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-16 | main | Jones Trading | Buy → Buy | $13 |
| 2024-08-14 | down | Maxim Group | Buy → Hold | — |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-15 | up | Brookline Capital | Hold → Buy | $3 |
| 2024-05-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-04-17 | down | Brookline Capital | Buy → Hold | — |
| 2024-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-11-10 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-07-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-06-06 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-05-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-03-31 | reit | HC Wainwright & Co. | — → Buy | $7 |
- Daré Bioscience schedules March 26 webcast for 2025 results - Stock Titan Fri, 20 Mar 2026 07
- Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates - finance.yahoo.com hu, 26 Mar 2026 07
- Dare Bioscience completes closing of Regulation A equity offering - Investing.com ue, 17 Mar 2026 07
- Why I Wouldn’t Dare Buy Palantir Stock’s Latest Bounce - 24/7 Wall St. Mon, 16 Mar 2026 07
- Daré Bioscience Completes Second Closing of Regulation A Offering - TipRanks Mon, 09 Mar 2026 07
- Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st Wed, 04 Feb 2026 08
- Dare Bioscience Breaks Out — But No News, Just Momentum - bitget.com Mon, 30 Mar 2026 03
- NIH funds hormone ring as preterm birth lacks FDA-approved treatment - Stock Titan Mon, 16 Mar 2026 07
- Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks ue, 17 Mar 2026 07
- Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com hu, 29 Jan 2026 08
- Dare Bioscience, Inc. (DARE) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - bitget.com hu, 26 Mar 2026 07
- Daré takes women's arousal cream to all 50 states ahead of Q2 sales - Stock Titan hu, 26 Mar 2026 07
- Persistent HPV has no FDA-approved drug; Daré CEO lays out DARE-HPV trial plan - Stock Titan hu, 12 Mar 2026 07
- Daré Bioscience (DARE) issues 43,050 preferred-and-warrant units - Stock Titan ue, 17 Mar 2026 07
- A Viagra ingredient is now in a topical cream developed for women - Stock Titan Mon, 23 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.03
+10429.36%
|
0.01
-99.65%
|
2.81
-71.92%
|
10.00
|
| Operating Revenue |
|
1.03
+10429.36%
|
0.01
-99.65%
|
2.81
-71.92%
|
10.00
|
| Cost Of Revenue |
|
0.30
|
—
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
0.30
|
—
|
—
|
—
|
| Gross Profit |
|
0.73
|
—
|
—
|
—
|
| Operating Expense |
|
14.29
-39.11%
|
23.46
-30.48%
|
33.75
-18.46%
|
41.39
|
| Research And Development |
|
5.52
-61.39%
|
14.31
-33.58%
|
21.54
-28.31%
|
30.04
|
| Selling General And Administration |
|
8.76
-4.29%
|
9.16
-24.39%
|
12.11
+7.71%
|
11.24
|
| General And Administrative Expense |
|
8.76
-4.29%
|
9.16
-24.39%
|
12.11
+7.71%
|
11.24
|
| Other Gand A |
|
8.76
-4.29%
|
9.16
-24.39%
|
12.11
+7.71%
|
11.24
|
| Other Operating Expenses |
|
—
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Total Expenses |
|
14.58
-37.84%
|
23.46
-30.48%
|
33.75
-18.46%
|
41.39
|
| Operating Income |
|
-13.55
+42.21%
|
-23.45
+24.20%
|
-30.94
+1.42%
|
-31.39
|
| Total Operating Income As Reported |
|
-13.55
+42.21%
|
-23.45
+24.20%
|
-30.94
+1.42%
|
-31.39
|
| EBITDA |
|
-11.92
+49.09%
|
-23.41
+24.25%
|
-30.90
+1.47%
|
-31.36
|
| Normalized EBITDA |
|
-11.92
+72.78%
|
-43.79
-41.70%
|
-30.90
+1.47%
|
-31.36
|
| Reconciled Depreciation |
|
1.63
+3761.75%
|
0.04
+10.33%
|
0.04
+58.51%
|
0.02
|
| EBIT |
|
-13.55
+42.21%
|
-23.45
+24.20%
|
-30.94
+1.42%
|
-31.39
|
| Total Unusual Items |
|
0.00
-100.00%
|
20.38
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-100.00%
|
20.38
|
0.00
|
0.00
|
| Special Income Charges |
|
0.00
-100.00%
|
20.38
|
0.00
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Pretax Income |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Other Income Expense |
|
0.15
-99.21%
|
19.40
+2391.74%
|
0.78
+77.84%
|
0.44
|
| Other Non Operating Income Expenses |
|
0.15
+115.59%
|
-0.98
-226.08%
|
0.78
+77.84%
|
0.44
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Net Income From Continuing Operation Net Minority Interest |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Net Income From Continuing And Discontinued Operation |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Net Income Continuous Operations |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Normalized Income |
|
-13.40
+45.16%
|
-24.43
+18.99%
|
-30.16
+2.54%
|
-30.95
|
| Net Income Common Stockholders |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
-1.20
-150.00%
|
-0.48
+88.43%
|
-4.15
+6.53%
|
-4.44
|
| Basic EPS |
|
-1.20
-150.00%
|
-0.48
+88.43%
|
-4.15
+6.53%
|
-4.44
|
| Basic Average Shares |
|
11.18
+31.55%
|
8.50
+16.80%
|
7.28
+3.23%
|
7.05
|
| Diluted Average Shares |
|
11.18
+31.55%
|
8.50
+16.80%
|
7.28
+3.23%
|
7.05
|
| Diluted NI Availto Com Stockholders |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Gain On Sale Of PPE |
|
0.00
-100.00%
|
20.38
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
32.47
+46.94%
|
22.10
+3.85%
|
21.28
-51.44%
|
43.83
|
| Current Assets |
|
27.06
+46.70%
|
18.45
+5.15%
|
17.54
-59.24%
|
43.04
|
| Cash Cash Equivalents And Short Term Investments |
|
24.71
+57.42%
|
15.70
+49.85%
|
10.48
-69.78%
|
34.67
|
| Cash And Cash Equivalents |
|
24.71
+57.42%
|
15.70
+49.85%
|
10.48
-69.78%
|
34.67
|
| Receivables |
|
0.57
+149.18%
|
0.23
-75.77%
|
0.95
-44.27%
|
1.70
|
| Other Receivables |
|
0.57
+149.18%
|
0.23
-75.77%
|
0.95
-44.27%
|
1.70
|
| Prepaid Assets |
|
1.39
-44.74%
|
2.52
-58.82%
|
6.12
-8.22%
|
6.67
|
| Current Deferred Assets |
|
0.32
|
0.00
|
—
|
—
|
| Other Current Assets |
|
0.07
|
—
|
—
|
—
|
| Total Non Current Assets |
|
5.41
+48.11%
|
3.65
-2.28%
|
3.74
+374.67%
|
0.79
|
| Net PPE |
|
4.40
+73.10%
|
2.54
+28.70%
|
1.98
+277.87%
|
0.52
|
| Gross PPE |
|
4.74
+74.33%
|
2.72
+28.16%
|
2.12
+305.73%
|
0.52
|
| Accumulated Depreciation |
|
-0.34
-92.17%
|
-0.18
-20.72%
|
-0.15
|
—
|
| Properties |
|
0.00
|
0.00
|
0.00
|
—
|
| Buildings And Improvements |
|
—
|
1.21
-8.54%
|
1.32
|
—
|
| Machinery Furniture Equipment |
|
0.05
+28.70%
|
0.04
-28.36%
|
0.05
|
—
|
| Construction In Progress |
|
0.00
-100.00%
|
1.23
+104.86%
|
0.60
|
—
|
| Other Properties |
|
4.65
+229.42%
|
1.41
-1.07%
|
1.43
+172.96%
|
0.52
|
| Leases |
|
0.04
+0.00%
|
0.04
-4.51%
|
0.04
|
—
|
| Non Current Deferred Assets |
|
—
|
—
|
—
|
0.14
|
| Non Current Prepaid Assets |
|
—
|
0.01
-98.97%
|
1.16
+10978.62%
|
0.01
|
| Other Non Current Assets |
|
1.01
-9.11%
|
1.11
+85.22%
|
0.60
+135.79%
|
0.25
|
| Total Liabilities Net Minority Interest |
|
29.63
+5.40%
|
28.11
+6.77%
|
26.33
-19.52%
|
32.71
|
| Current Liabilities |
|
23.69
+9.59%
|
21.61
+5.53%
|
20.48
-35.24%
|
31.62
|
| Payables And Accrued Expenses |
|
1.92
-48.13%
|
3.69
-32.47%
|
5.47
-51.17%
|
11.20
|
| Payables |
|
1.38
-18.90%
|
1.71
-53.39%
|
3.66
+80.44%
|
2.03
|
| Accounts Payable |
|
1.20
-17.53%
|
1.46
-57.00%
|
3.39
+66.94%
|
2.03
|
| Other Payable |
|
0.18
-26.88%
|
0.25
-8.79%
|
0.27
|
—
|
| Current Accrued Expenses |
|
0.53
-73.21%
|
1.99
+9.82%
|
1.81
-80.27%
|
9.17
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.01
-98.73%
|
0.81
+0.02%
|
0.81
-53.19%
|
1.72
|
| Current Debt And Capital Lease Obligation |
|
2.10
+282.16%
|
0.55
+17.05%
|
0.47
+17.65%
|
0.40
|
| Current Capital Lease Obligation |
|
2.10
+282.16%
|
0.55
+17.05%
|
0.47
+17.65%
|
0.40
|
| Current Deferred Liabilities |
|
19.65
+18.66%
|
16.56
+20.56%
|
13.74
-24.95%
|
18.30
|
| Current Deferred Revenue |
|
19.65
+18.66%
|
16.56
+20.56%
|
13.74
-24.95%
|
18.30
|
| Other Current Liabilities |
|
0.01
+188.88%
|
0.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
5.95
-8.52%
|
6.50
+11.12%
|
5.85
+436.47%
|
1.09
|
| Long Term Debt And Capital Lease Obligation |
|
0.56
-25.85%
|
0.75
-19.38%
|
0.94
+935.73%
|
0.09
|
| Long Term Capital Lease Obligation |
|
0.56
-25.85%
|
0.75
-19.38%
|
0.94
+935.73%
|
0.09
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
1.00
+0.00%
|
1.00
+0.00%
|
1.00
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
1.00
+0.00%
|
1.00
+0.00%
|
1.00
|
| Other Non Current Liabilities |
|
5.39
+13.51%
|
4.75
+21.26%
|
3.91
|
—
|
| Stockholders Equity |
|
2.84
+147.28%
|
-6.01
-19.11%
|
-5.05
-145.42%
|
11.11
|
| Common Stock Equity |
|
2.84
+147.28%
|
-6.01
-19.11%
|
-5.05
-145.42%
|
11.11
|
| Capital Stock |
|
0.00
+66.67%
|
0.00
+4.44%
|
0.00
-90.18%
|
0.01
|
| Common Stock |
|
0.00
+66.67%
|
0.00
+4.44%
|
0.00
-90.18%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
14.50
+66.65%
|
8.70
+4.43%
|
8.33
+17.86%
|
7.07
|
| Ordinary Shares Number |
|
14.50
+66.65%
|
8.70
+4.43%
|
8.33
+17.86%
|
7.07
|
| Additional Paid In Capital |
|
191.95
+13.11%
|
169.71
+1.90%
|
166.55
+9.19%
|
152.53
|
| Retained Earnings |
|
-188.69
-7.64%
|
-175.29
-2.37%
|
-171.24
-21.38%
|
-141.07
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.42
+1.68%
|
-0.43
-18.82%
|
-0.36
-2.73%
|
-0.35
|
| Other Equity Adjustments |
|
-0.42
+1.68%
|
-0.43
-18.82%
|
-0.36
-2.73%
|
-0.35
|
| Total Equity Gross Minority Interest |
|
2.84
+147.28%
|
-6.01
-19.11%
|
-5.05
-145.42%
|
11.11
|
| Total Capitalization |
|
2.84
+147.28%
|
-6.01
-19.11%
|
-5.05
-145.42%
|
11.11
|
| Working Capital |
|
3.38
+206.73%
|
-3.17
-7.77%
|
-2.94
-125.73%
|
11.41
|
| Invested Capital |
|
2.84
+147.28%
|
-6.01
-19.11%
|
-5.05
-145.42%
|
11.11
|
| Total Debt |
|
2.66
+103.84%
|
1.30
-7.22%
|
1.40
+187.37%
|
0.49
|
| Capital Lease Obligations |
|
2.66
+103.84%
|
1.30
-7.22%
|
1.40
+187.37%
|
0.49
|
| Net Tangible Assets |
|
2.84
+147.28%
|
-6.01
-19.11%
|
-5.05
-145.42%
|
11.11
|
| Tangible Book Value |
|
2.84
+147.28%
|
-6.01
-19.11%
|
-5.05
-145.42%
|
11.11
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-9.89
-280.61%
|
5.47
+114.09%
|
-38.86
-114.81%
|
-18.09
|
| Cash Flow From Continuing Operating Activities |
|
-9.89
-280.61%
|
5.47
+114.09%
|
-38.86
-114.81%
|
-18.09
|
| Net Income From Continuing Operations |
|
-13.40
-230.55%
|
-4.05
+86.56%
|
-30.16
+2.54%
|
-30.95
|
| Depreciation Amortization Depletion |
|
1.63
+3761.75%
|
0.04
+10.33%
|
0.04
+58.51%
|
0.02
|
| Depreciation |
|
1.63
+3761.75%
|
0.04
+10.33%
|
0.04
+58.51%
|
0.02
|
| Depreciation And Amortization |
|
1.63
+3761.75%
|
0.04
+10.33%
|
0.04
+58.51%
|
0.02
|
| Other Non Cash Items |
|
-0.40
-150.82%
|
0.79
+194.14%
|
-0.84
-3531.16%
|
-0.02
|
| Stock Based Compensation |
|
1.50
-32.07%
|
2.20
-12.94%
|
2.53
+17.24%
|
2.16
|
| Operating Gains Losses |
|
-0.01
-101.05%
|
0.60
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
-0.01
-101.05%
|
0.60
|
0.00
|
—
|
| Change In Working Capital |
|
0.79
-86.61%
|
5.89
+156.52%
|
-10.43
-197.45%
|
10.70
|
| Change In Receivables |
|
-0.34
-147.70%
|
0.72
-4.60%
|
0.75
+235.15%
|
-0.56
|
| Changes In Account Receivables |
|
-0.01
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
0.67
-83.29%
|
4.00
+761.03%
|
-0.61
+85.55%
|
-4.19
|
| Change In Payables And Accrued Expense |
|
-1.93
-56.23%
|
-1.24
+82.10%
|
-6.91
-190.00%
|
7.68
|
| Change In Accrued Expense |
|
-1.68
-342.39%
|
0.69
+108.37%
|
-8.27
-206.63%
|
7.76
|
| Change In Payable |
|
-0.26
+86.78%
|
-1.93
-242.14%
|
1.36
+1906.95%
|
-0.08
|
| Change In Account Payable |
|
-0.26
+86.78%
|
-1.93
-242.14%
|
1.36
+1906.95%
|
-0.08
|
| Change In Other Working Capital |
|
3.09
+9.39%
|
2.82
+161.85%
|
-4.57
-158.84%
|
7.76
|
| Change In Other Current Assets |
|
-0.14
-416.33%
|
0.05
+542.35%
|
-0.01
-382.19%
|
0.00
|
| Change In Other Current Liabilities |
|
-0.55
-19.33%
|
-0.46
-150.21%
|
0.92
|
—
|
| Investing Cash Flow |
|
-0.39
+32.77%
|
-0.57
+8.96%
|
-0.63
-898.00%
|
-0.06
|
| Cash Flow From Continuing Investing Activities |
|
-0.39
+32.77%
|
-0.57
+8.96%
|
-0.63
-898.00%
|
-0.06
|
| Net PPE Purchase And Sale |
|
-0.39
+32.77%
|
-0.57
+8.96%
|
-0.63
-898.00%
|
-0.06
|
| Purchase Of PPE |
|
-0.39
+32.77%
|
-0.57
+8.96%
|
-0.63
-898.00%
|
-0.06
|
| Capital Expenditure |
|
-0.39
+32.77%
|
-0.57
+8.96%
|
-0.63
-898.00%
|
-0.06
|
| Financing Cash Flow |
|
19.28
+5337.50%
|
0.35
-97.73%
|
15.64
+1064.04%
|
1.34
|
| Cash Flow From Continuing Financing Activities |
|
19.28
+5337.50%
|
0.35
-97.73%
|
15.64
+1064.04%
|
1.34
|
| Net Issuance Payments Of Debt |
|
-1.33
-7481.41%
|
-0.02
-106.57%
|
0.27
|
0.00
|
| Issuance Of Debt |
|
0.49
-13.34%
|
0.56
-6.57%
|
0.60
|
0.00
|
| Repayment Of Debt |
|
-1.82
-213.87%
|
-0.58
-73.43%
|
-0.33
|
0.00
|
| Long Term Debt Issuance |
|
0.49
-13.34%
|
0.56
-6.57%
|
0.60
|
0.00
|
| Long Term Debt Payments |
|
-1.82
-213.87%
|
-0.58
-73.43%
|
-0.33
|
0.00
|
| Net Long Term Debt Issuance |
|
-1.33
-7481.41%
|
-0.02
-106.57%
|
0.27
|
0.00
|
| Net Common Stock Issuance |
|
20.93
+4514.44%
|
0.45
-95.15%
|
9.35
+666.91%
|
1.22
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
-100.00%
|
1.30
+942.80%
|
0.12
|
| Net Other Financing Charges |
|
-0.32
-294.72%
|
-0.08
-101.73%
|
4.72
|
—
|
| Changes In Cash |
|
9.01
+71.38%
|
5.26
+122.03%
|
-23.85
-41.89%
|
-16.81
|
| Effect Of Exchange Rate Changes |
|
0.01
+110.58%
|
-0.07
-608.53%
|
-0.01
+95.12%
|
-0.20
|
| Beginning Cash Position |
|
16.00
+47.98%
|
10.81
-68.82%
|
34.67
-32.91%
|
51.67
|
| End Cash Position |
|
25.01
+56.34%
|
16.00
+47.98%
|
10.81
-68.82%
|
34.67
|
| Free Cash Flow |
|
-10.27
-309.59%
|
4.90
+112.41%
|
-39.49
-117.54%
|
-18.15
|
| Change In Interest Payable |
|
0.57
+9.94%
|
0.52
|
0.00
|
—
|
| Common Stock Issuance |
|
20.93
+4514.44%
|
0.45
-95.15%
|
9.35
+666.91%
|
1.22
|
| Issuance Of Capital Stock |
|
20.93
+4514.44%
|
0.45
-95.15%
|
9.35
+666.91%
|
1.22
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 8-K2026-03-17 View
- 8-K2026-03-09 View
- 8-K2026-03-02 View
- 42026-02-20 View
- 42026-02-02 View
- 42026-02-02 View
- 8-K2026-01-29 View
- 8-K2026-01-06 View
- 8-K2025-12-01 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 42025-09-04 View
- 8-K2025-09-02 View
- 10-Q2025-08-14 View
- 8-K2025-08-14 View
- 8-K2025-07-25 View
- 8-K2025-07-21 View
- 8-K2025-07-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|